NeurAxis, Inc. (NRXS)
:NRXS
Earnings Data
Report Date
May 27, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.33Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated a clear progression from regulatory and coverage milestones toward commercialization: a Category I CPT code, a ~45M member major payer policy, an FSS contract with the VA, sustained unit and revenue growth, and strengthened liquidity. Management also outlined concrete commercial hiring and payer engagement plans and multiple ongoing clinical trials to expand adult and other-indication coverage. Offsetting these positives are margin compression driven by product mix and inventory adjustments, higher operating expenses that increased quarterly losses, uneven hospital adoption due to operational/administrative barriers, and the need for additional payer policies (and an adult RCT) to unlock broader adoption. Overall, the upside from reimbursement wins, regulatory progress, accelerating submissions and funded runway meaningfully outweighs the execution and margin challenges in the near term.Company Guidance
Category I CPT Code Effective Jan 1, 2026
Company secured a Category I CPT code effective January 1, 2026, shifting focus from access creation to commercial execution; management cited this as a major catalyst enabling scaled reimbursement efforts and stated the combined coverage footprint now exceeds 100 million covered lives (company statement).
Major Payer Policy Coverage — ~45 Million Members
In December the company obtained written medical policy coverage from a major national insurer representing approximately 45 million health plan members; this coverage provided immediate full reimbursement (no prior authorization required with correct diagnosis codes) and helped drive a favorable mix shift in Q4.
Federal Supply Schedule (FSS) Contract with VA
Awarded an FSS contract enabling access to the U.S. Department of Veterans Affairs (serving ~7 million active patients annually); management reported multiple VA facilities placing orders and early reorders, representing a new federal channel for growth.
Revenue and Unit Growth
Q4 2025 revenue $968k, up 27% vs Q4 2024 ($761k); Q4 unit deliveries increased 35% y/y. Fiscal 2025 revenue $3.6M, up 33% vs FY2024 ($2.7M); fiscal unit deliveries increased 44% y/y. Company reported the seventh straight quarter of double-digit unit growth.
Commercial Scaling and Reimbursement Infrastructure
Management outlined targeted commercial initiatives (engagement with ~75 children's hospitals, CME presentations, payer-focused marketing, expansion of prior-authorization team) and hiring plans for MSLs, market development specialists, digital marketing, and sales to support 2026 commercialization.
Clinical and Regulatory Progress
Key clinical/regulatory milestones achieved: FDA indication expansion to functional abdominal pain and functional dyspepsia (children and adults), label expansion to ages 8+, increase to four devices per treatment, publication of NASPA/academic society guidelines, initiation of a Cleveland Clinic randomized controlled trial in adults, and other ongoing RCTs (cyclic vomiting syndrome, a 300‑patient post-op UPMC study).
Improved Liquidity and Cash Position
Cash on hand as of 12/31/2025 was $5.0M; Q4 free cash flow was $2.5M (exceeding core quarterly burn of $1.5M). Since quarter end the company raised an incremental $2.6M (ATM and warrant exercises) and reported current cash >$6M with ~$1.2M remaining on the ATM, indicating sufficient near-term liquidity per management.
NRXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NRXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 19, 2026 | $6.99 | $7.16 | +2.43% |
Nov 11, 2025 | $2.56 | $2.41 | -5.86% |
Aug 12, 2025 | $2.43 | $2.49 | +2.47% |
May 12, 2025 | $2.00 | $2.32 | +16.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NeurAxis, Inc. (NRXS) report earnings?
NeurAxis, Inc. (NRXS) is schdueled to report earning on May 27, 2026, Before Open (Confirmed).
What is NeurAxis, Inc. (NRXS) earnings time?
NeurAxis, Inc. (NRXS) earnings time is at May 27, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NRXS EPS forecast?
NRXS EPS forecast for the fiscal quarter 2026 (Q1) is -0.2.